brivanib

"Brivanib has been investigated for the treatment of Solid Tumors, Hepato Cellular Carcinoma (HCC), and Metastatic Colorectal Cancer (MCRC). It is under investigation for the treatment of HepatoCellular Carcinoma. . Reference standards of Brivanib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below

stdClass Object
(
    [pname] => Brivanib
    [catalogue_number] => PA 02 45000
    [category_ids] => ,69,78,70,82,89,
    [chemical_name] => 
    [weight] => 370.38
    [form] => C19H19FN4O3
    [cas] => 649735-46-6
    [pslug] => 649735-46-6-brivanib-api-pa0245000
    [latest_product] => 0
    [linkproducts] => 0
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)
PA 02 45000

Brivanib


  • Catalogue No.:PA 02 45000

  • CAS :

    649735-46-6

  • Molecular Formula : C19H19FN4O3

  • Molecular Weight : 370.38

CPHI INDIA- 28, 30 November